PMC10350683_01
Tumor evaluation by chest-CT and brain MRI.
fonc-13-1143775-g001.jpg
PMC10350683_01_fonc-13-1143775-g001.jpg
f1
Osimertinib treatment was continued as there was no progression of the other tumor locations ( Figure 1  - April 2022).
August 2022: oligometastatic lung progression.
fonc-13-1143775-g002.jpg
PMC10350683_01_fonc-13-1143775-g002.jpg
f2
Osimertinib treatment was continued as there was no progression of the other tumor locations ( Figure 1  - April 2022). In August 2022, 30 months after the initiation of osimertinib, the patient presented a focal asymptomatic progression in the main left thoracic lesion, without signs of other extracerebral or cerebral progression, as confirmed by PET-scan ( Figure 2 ) and brain MRI.
Crystallographic structure of the EGFR protein.
fonc-13-1143775-g003.jpg
PMC10350683_01_fonc-13-1143775-g003.jpg
f3
Osimertinib treatment was continued as there was no progression of the other tumor locations ( Figure 1  - April 2022).